Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Cytohesin-3 is required for full insulin receptor signaling and controls body weight via lipid excretion.

Jux B, Gosejacob D, Tolksdorf F, Mandel C, Rieck M, Namislo A, Pfeifer A, Kolanus W.

Sci Rep. 2019 Mar 5;9(1):3442. doi: 10.1038/s41598-019-40231-3.

2.

Memory T cells specific to citrullinated α-enolase are enriched in the rheumatic joint.

Pieper J, Dubnovitsky A, Gerstner C, James EA, Rieck M, Kozhukh G, Tandre K, Pellegrino S, Gebe JA, Rönnblom L, Sandalova T, Kwok WW, Klareskog L, Buckner JH, Achour A, Malmström V.

J Autoimmun. 2018 Aug;92:47-56. doi: 10.1016/j.jaut.2018.04.004. Epub 2018 May 28.

3.

Corrigendum: Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid Arthritis.

Gerstner C, Dubnovitsky A, Sandin C, Kozhukh G, Uchtenhagen H, James EA, Rönnelid J, Ytterberg AJ, Pieper J, Reed E, Tandre K, Rieck M, Zubarev RA, Rönnblom L, Sandalova T, Buckner JH, Achour A, Malmström V.

Front Immunol. 2017 Oct 4;8:1236. doi: 10.3389/fimmu.2017.01236. eCollection 2017.

4.

Ceramide synthase 2 facilitates S1P-dependent egress of thymocytes into the circulation in mice.

Rieck M, Kremser C, Jobin K, Mettke E, Kurts C, Gräler M, Willecke K, Kolanus W.

Eur J Immunol. 2017 Apr;47(4):677-684. doi: 10.1002/eji.201646623. Epub 2017 Feb 27.

5.

Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid Arthritis.

Gerstner C, Dubnovitsky A, Sandin C, Kozhukh G, Uchtenhagen H, James EA, Rönnelid J, Ytterberg AJ, Pieper J, Reed E, Tandre K, Rieck M, Zubarev RA, Rönnblom L, Sandalova T, Buckner JH, Achour A, Malmström V.

Front Immunol. 2016 Nov 14;7:494. eCollection 2016. Erratum in: Front Immunol. 2017 Oct 04;8:1236.

6.

Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.

Rieck M, Schumacher-Schuh AF, Altmann V, Callegari-Jacques SM, Rieder CRM, Hutz MH.

Pharmacogenomics J. 2018 Jan;18(1):196-200. doi: 10.1038/tpj.2016.79. Epub 2016 Oct 25.

PMID:
27779245
7.

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.

Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH.

Pharmacogenomics. 2016 Apr;17(5):481-8. doi: 10.2217/pgs.15.183. Epub 2016 Mar 29.

PMID:
27019953
8.

Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment.

Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH.

Neurosci Lett. 2016 Feb 26;615:88-91. doi: 10.1016/j.neulet.2016.01.030. Epub 2016 Jan 21.

9.

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.

Kuipers HF, Rieck M, Gurevich I, Nagy N, Butte MJ, Negrin RS, Wight TN, Steinman L, Bollyky PL.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1339-44. doi: 10.1073/pnas.1525086113. Epub 2016 Jan 19.

10.

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q.

Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.

11.

Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?

Rieck M, Schumacher-Schuh AF, Callegari-Jacques SM, Altmann V, Schneider Medeiros M, Rieder CR, Hutz MH.

Pharmacogenomics. 2015;16(6):573-82. doi: 10.2217/pgs.15.23. Epub 2015 Apr 15.

PMID:
25872644
12.

Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy.

James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, Peda M, Sandin C, Klareskog L, Malmström V, Buckner JH.

Arthritis Rheumatol. 2014 Jul;66(7):1712-22. doi: 10.1002/art.38637.

13.

Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.

Pieper J, Johansson S, Snir O, Linton L, Rieck M, Buckner JH, Winqvist O, van Vollenhoven R, Malmström V.

Scand J Immunol. 2014 Feb;79(2):149-55. doi: 10.1111/sji.12139.

14.

Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.

Schumacher-Schuh AF, Altmann V, Rieck M, Tovo-Rodrigues L, Monte TL, Callegari-Jacques SM, Medeiros MS, Rieder CR, Hutz MH.

Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15.

PMID:
24126708
15.

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Bollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ.

Clin Exp Immunol. 2013 Jun;172(3):363-74. doi: 10.1111/cei.12064.

16.

DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.

Rieck M, Schumacher-Schuh AF, Altmann V, Francisconi CL, Fagundes PT, Monte TL, Callegari-Jacques SM, Rieder CR, Hutz MH.

Pharmacogenomics. 2012 Nov;13(15):1701-10. doi: 10.2217/pgs.12.149.

PMID:
23171335
17.

Identification of novel HLA class II target epitopes for generation of donor-specific T regulatory cells.

Stone B, Rieck M, Rawlings CA, Kas A, Shendure J, Jones H, Buckner JH.

Clin Immunol. 2012 Nov;145(2):153-60. doi: 10.1016/j.clim.2012.09.003. Epub 2012 Sep 19.

PMID:
23063892
18.

Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression.

Behnken A, Bellingrath S, Symanczik JP, Rieck MJ, Zavorotnyy M, Domschke K, Arolt V, Zwanzger P.

Psychoneuroendocrinology. 2013 Mar;38(3):447-54. doi: 10.1016/j.psyneuen.2012.07.005. Epub 2012 Jul 26.

PMID:
22840287
19.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

20.

Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant.

Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C, Rawlings DJ, Buckner JH.

J Immunol. 2012 Jan 1;188(1):487-96. doi: 10.4049/jimmunol.1102176. Epub 2011 Nov 21.

21.

Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells.

Long SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH.

J Immunol. 2011 Oct 1;187(7):3511-20. doi: 10.4049/jimmunol.1003880. Epub 2011 Aug 24.

22.

Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients.

Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, Malmström V, Buckner JH.

Arthritis Rheum. 2011 Oct;63(10):2873-83. doi: 10.1002/art.30445.

23.

Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.

Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, Pihoker C, Greenbaum C, Nepom GT, Buckner JH.

Eur J Immunol. 2009 Feb;39(2):612-20. doi: 10.1002/eji.200838819.

24.

The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.

Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH.

J Immunol. 2008 Nov 15;181(10):7350-5.

25.

Regulation of Cell Proliferation and Differentiation by PPARbeta/delta.

Müller R, Rieck M, Müller-Brüsselbach S.

PPAR Res. 2008;2008:614852. doi: 10.1155/2008/614852.

26.

Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid.

Rieck M, Meissner W, Ries S, Müller-Brüsselbach S, Müller R.

Mol Pharmacol. 2008 Nov;74(5):1269-77. doi: 10.1124/mol.108.050625. Epub 2008 Aug 13.

PMID:
18701617
27.

T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.

Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, Tomblingson GW, Lingappa JR.

PLoS Pathog. 2007 Sep 21;3(9):1320-34.

28.

Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.

Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH.

J Immunol. 2007 Oct 1;179(7):4704-10.

29.

Expression level and agonist-binding affect the turnover, ubiquitination and complex formation of peroxisome proliferator activated receptor beta.

Rieck M, Wedeken L, Müller-Brüsselbach S, Meissner W, Müller R.

FEBS J. 2007 Oct;274(19):5068-76. Epub 2007 Sep 4.

30.

Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta.

Degenhardt T, Saramäki A, Malinen M, Rieck M, Väisänen S, Huotari A, Herzig KH, Müller R, Carlberg C.

J Mol Biol. 2007 Sep 14;372(2):341-55. Epub 2007 Jul 19.

PMID:
17669420
31.

Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice.

Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, Peters JM, Müller R.

EMBO J. 2007 Aug 8;26(15):3686-98. Epub 2007 Jul 19.

32.

Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene.

Adamkiewicz J, Kaddatz K, Rieck M, Wilke B, Müller-Brüsselbach S, Müller R.

Proteomics. 2007 Apr;7(8):1208-16.

PMID:
17380536
33.
35.

Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta.

Fauti T, Müller-Brüsselbach S, Kreutzer M, Rieck M, Meissner W, Rapp U, Schweer H, Kömhoff M, Müller R.

FEBS J. 2006 Jan;273(1):170-9. Erratum in: FEBS J. 2006 Feb;273(3):669-71.

36.

Multidimensional nature of posttraumatic growth in an Australian population.

Morris BA, Shakespeare-Finch J, Rieck M, Newbery J.

J Trauma Stress. 2005 Oct;18(5):575-85.

PMID:
16281257
37.

Comparison of four clinical tests for assessing hamstring muscle length.

Gajdosik RL, Rieck MA, Sullivan DK, Wightman SE.

J Orthop Sports Phys Ther. 1993 Nov;18(5):614-8.

PMID:
8268964
38.
39.

Metabolic products of microorganisms. 258. Enzymatic bromination of nikkomycin Z.

Decker H, Pfefferle U, Bormann C, Zähner H, Fiedler HP, Van Pée KH, Rieck M, König WA.

J Antibiot (Tokyo). 1991 Jun;44(6):626-34.

40.
41.

Controlled psychodiagnostic studies of survivors of the Holocaust and their children.

Rieck M, Eitinger L.

Isr J Psychiatry Relat Sci. 1983;20(4):312-24. No abstract available.

PMID:
6678886
42.

[Solitary ulcer of the rectum].

Rieck M, Halter F.

Minerva Med. 1972 Aug 18;63(58):3166-8. Italian. No abstract available.

PMID:
5052668
43.

A test of satiation as a function of adaptation in stuttering.

Peterson HA, Rieck MB, Hoff RK.

J Speech Hear Res. 1969 Mar;12(1):110-7. No abstract available.

PMID:
5779895

Supplemental Content

Support Center